JM Financial is bullish on Mounjaro's success in India, citing its price advantage, higher efficiency and the country's large ...
Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback